Multiple Sclerosis News

 
 
  • ECTRIMS 2020 Multiple Sclerosis Prodrome Holds Promise of Earlier Diagnosis There is now no doubt that a prodromal phase of MS exists for several years before the first demyelinating event occurs, latest evidence shows.
  • ECTRIMS 2020 NfL Blood Biomarker Captures Suboptimal Treatment Response in MS Measuring levels of neurofilament light chain is an effective way of detecting disease activity and the need to optimize treatment in patients with multiple sclerosis, independent of other measures, a new study shows.
  • ECTRIMS 2020 App for MS Aims to Capture Elusive Signals of Progression Investigators in Switzerland are testing an application for smartphones that they hope will elucidate subtle signs of disease progression in multiple sclerosis (MS) -- beyond what standard imaging and clinical biomarkers can tell them.
  • ECTRIMS 2020 Lessons for Patients With MS and COVID-19 Two lessons about managing patients with MS and COVID-19 have emerged: Combined PCR and serology helped avoid disease reactivation in asymptomatic carriers during the pandemic peak, and infected MS patients could stay on MS drugs during COVID-19 treatment.
  • ECTRIMS 2020 Satralizumab Reduces Risk of Severe NMOSD Relapse Compared with placebo, satralizumab reduces the risk of severe relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).
  • ECTRIMS 2020 Cardiovascular Risk Factors Linked to Brain Atrophy in MS Even low levels of exposure to cardiovascular risk factors are important in MS and might affect brain volume loss, a new study suggests.
  • In MS, Serious AEs More Common in Rituximab vs Ocrelizumab
  • ECTRIMS 2020 Smoking Increases Risk of High Plasma NfL Levels in MS A study has found that patients with multiple sclerosis who smoke have an increased risk of higher plasma neurofilament light levels (pNfL), which increase disease activity and reduce response to treatment.
  • Lowering Rituximab Dose in Patients With MS Safe, Effective A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and stable choice for patients with multiple sclerosis.
  • Roche Studies Ocrevus, Experimental Drug in Bid to Defend MS Franchise Roche aims to defend its multiple sclerosis franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.
  • Six Potential Treatments for COVID-19 Identified Artificial intelligence is helping researchers identify existing drugs and drug combinations that may be repurposed in the fight against COVID-19.
  • Choroid Plexuses May Play a Role in Migraine Levels of soluble vascular cell adhesion molecule 1 in cerebrospinal fluid could serve as a biomarker of the mechanisms underlying migraine.
  • TNF Inhibitors Linked to Inflammatory CNS Events Use of tumor necrosis factor inhibitors in patients with autoimmune diseases may increase risk for inflammatory demyelinating and non-demyelinating central nervous system events, new data suggest.
  • Alert FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS The FDA has approved ofatumumab (Kesimpta) as the first self-administered, targeted B-cell therapy for adults with relapsing forms of multiple sclerosis.
  • US Sues Teva Over Alleged Kickbacks for Multiple Sclerosis Drug The lawsuit accuses the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks it paid for its multiple sclerosis drug Copaxone.
  • FDA OKs Satralizumab (Enspryng) for NMOSD Satralizumab is a humanized monoclonal antibody that inhibits interleukin-6 receptor activity, believed to play a key role in the inflammation associated with NMOSD.
  • NIAID Testing Remdesivir Plus MS Drug for COVID-19 The ACTT-3 randomized controlled trial is testing the safety and efficacy remdesivir in combination with the immunomodulator interferon beta-1a in hospitalized COVID-19 patients.
  • Ofatumumab Phase 3 Multiple Sclerosis Trials Published The B-cell depleting drug given by subcutaneous injection showed lower annualized relapse rates and less disability worsening than teriflunomide in the ASCLEPIOS I and II trials.
  • Alert CHMP Backs Bupivacaine/Meloxicam (Zynrelef) for Postop Pain The CHMPS has recommended granting marketing authorization for the nonopioid drug to treat surgical pain, as well as for a generic form of Fampyra to treat multiple sclerosis associated with walking disability.
  • CMSC 2020 Influenza Vaccine Efficacy 'Undiminished' in MS The efficacy of the influenza vaccine when given to patients with multiple sclerosis is similar to that in healthy controls, according to an analysis of nine published cohort studies.